WO2023036820 - THERAPEUTIC USES OF 1-[2-(2,4-DIMETHYL-PHENYLSULFANYL)PHENYL]PIPERAZINE
National phase entry is expected:
Publication Number
WO/2023/036820
Publication Date
16.03.2023
International Application No.
PCT/EP2022/074860
International Filing Date
07.09.2022
Title **
[English]
THERAPEUTIC USES OF 1-[2-(2,4-DIMETHYL-PHENYLSULFANYL)PHENYL]PIPERAZINE
[French]
UTILISATIONS THÉRAPEUTIQUES DE 1-[2-(2,4-DIMÉTHYL-PHÉNYLSULFANYL)PHÉNYL]PIPÉRAZINE
Applicants **
H. LUNDBECK A/S
Ottiliavej 9
2500 Valby, DK
Inventors
EBERT, Bjarke
2500 Valby, DK
MCINTYRE, Roger S.
2500 Valby, DK
SPANNHUTH, Carsten Walter
2500 Valby, DK
FREIHERR VON DER GOLTZ, Christoph
2500 Valby, DK
Priority Data
21196078.6
10.09.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1002 | |
| EPO | Filing, Examination | 4674 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 9550 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention provides therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine or a pharmaceutically acceptable salt thereof in the treatment of signs and symptoms of post COVID-19 syndrome or ongoing symptomatic COVID-19.[French]
L'invention concerne des utilisations thérapeutiques de 1-[2-(2,4-diméthyl-phénylsulfanyl)phényl]pipérazine ou un sel pharmaceutiquement acceptable de celle-ci dans le traitement de signes et de symptômes du syndrome post-COVID-19 ou du COVID19 symptomatique en cours.